{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:43:13Z","timestamp":1761864193986,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Merck Biopharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10147-020-01817-4","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T10:03:01Z","timestamp":1604052181000},"page":"316-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2)"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7327-7949","authenticated-orcid":false,"given":"Tomoya","family":"Yokota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kodaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torahiko","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuya","family":"Monden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"1817_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.6004\/jnccn.2012.0084","volume":"10","author":"S Baxi","year":"2012","unstructured":"Baxi S, Fury M, Ganly I et al (2012) Ten years of progress in head and neck cancers. J Natl Compr Canc Netw 10:806\u2013810","journal-title":"J Natl Compr Canc Netw"},{"key":"1817_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.1992.10.2.257","volume":"10","author":"C Jacobs","year":"1992","unstructured":"Jacobs C, Lyman G, Velez-Garc\u00eda E et al (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257\u2013263","journal-title":"J Clin Oncol"},{"key":"1817_CR3","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","volume":"10","author":"AA Forastiere","year":"1992","unstructured":"Forastiere AA, Metch B, Schuller DE et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck. J Clin Oncol 10:1245\u20131251","journal-title":"J Clin Oncol"},{"key":"1817_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/jnci\/90.11.824","volume":"90","author":"JR Grandis","year":"1998","unstructured":"Grandis JR, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824\u2013832","journal-title":"J Natl Cancer Inst"},{"key":"1817_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1517\/14728222.10.5.639","volume":"10","author":"AM Egloff","year":"2006","unstructured":"Egloff AM, Grandis J (2006) Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin Ther Targets 10:639\u2013647","journal-title":"Expert Opin Ther Targets"},{"key":"1817_CR6","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1200\/JCO.2006.07.2587","volume":"24","author":"CH Chung","year":"2006","unstructured":"Chung CH, Ely K, McGavran L et al (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170\u20134176","journal-title":"J Clin Oncol"},{"key":"1817_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116\u20131127","journal-title":"N Engl J Med"},{"key":"1817_CR8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/jjco\/hyt034","volume":"43","author":"T Yoshino","year":"2013","unstructured":"Yoshino T, Hasegawa Y, Takahashi S et al (2013) Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial. Jpn J Clin Oncol 43:524\u2013531","journal-title":"Jpn J Clin Oncol"},{"key":"1817_CR9","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915\u20131928","journal-title":"Lancet"},{"key":"1817_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856\u20131867","journal-title":"N Engl J Med"},{"key":"1817_CR11","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171\u20132177","journal-title":"J Clin Oncol"},{"key":"1817_CR12","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/annonc\/mdr367","volume":"23","author":"R Hitt","year":"2012","unstructured":"Hitt R, Irigoyen A, Cortes-Funes H et al (2012) Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 23:1016\u20131022","journal-title":"Ann Oncol"},{"key":"1817_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s12094-016-1604-z","volume":"19","author":"IP Bernad","year":"2017","unstructured":"Bernad IP, Trufero JM, Urquizu LC et al (2017) Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent\/metastatic head and neck squamous cell carcinoma: prognostic factors. Clin Transl Oncol 19:769\u2013776","journal-title":"Clin Transl Oncol"},{"key":"1817_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000345453","volume":"84","author":"M Knoedler","year":"2013","unstructured":"Knoedler M, Gauler TC, Gruenwald V et al (2013) Phase II study of cetuximab in combination with docetaxel in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology 84:284\u2013289","journal-title":"Oncology"},{"key":"1817_CR15","doi-asserted-by":"publisher","first-page":"32946","DOI":"10.1038\/srep32946","volume":"6","author":"D Posch","year":"2016","unstructured":"Posch D, Fuchs H, Kornek G et al (2016) Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent\/metastatic head and neck cancer. Sci Rep 6:32946","journal-title":"Sci Rep"},{"key":"1817_CR16","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/annonc\/mdy040","volume":"29","author":"M Tahara","year":"2018","unstructured":"Tahara M, Kiyota N, Yokota T et al (2018) Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol 29:1004\u20131009","journal-title":"Ann Oncol"},{"key":"1817_CR17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jclinepi.2009.07.013","volume":"63","author":"N Freemantle","year":"2010","unstructured":"Freemantle N, Strack T (2010) Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. J Clin Epidemiol 63:1053\u20131058","journal-title":"J Clin Epidemiol"},{"key":"1817_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jval.2014.10.009","volume":"18","author":"ML Berger","year":"2015","unstructured":"Berger ML, Lipset C, Gutteridge A et al (2015) Optimizing the leveraging of real-world data to improve the development and use of medicines. Value Health 18:127\u2013130","journal-title":"Value Health"},{"key":"1817_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejca.2019.03.022","volume":"115","author":"R Depenni","year":"2019","unstructured":"Depenni R, Cossu Rocca M, Ferrari D et al (2019) Clinical outcomes and prognostic factors in recurrent and\/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. Eur J Cancer 115:4\u201312","journal-title":"Eur J Cancer"},{"key":"1817_CR20","doi-asserted-by":"publisher","first-page":"74362","DOI":"10.18632\/oncotarget.11413","volume":"7","author":"P Bossi","year":"2016","unstructured":"Bossi P, Resteghini C, Paielli N et al (2016) Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. Oncotarget 7:74362\u201374379","journal-title":"Oncotarget"},{"key":"1817_CR21","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.20640","volume":"101","author":"A Argiris","year":"2004","unstructured":"Argiris A, Li Y, Forastiere A (2004) Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101:2222\u20132229","journal-title":"Cancer"},{"key":"1817_CR22","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1200\/JCO.2011.40.9243","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tejpar S, Vanbeckevoort D et al (2012) Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 30:2861\u20132868","journal-title":"J Clin Oncol"},{"key":"1817_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"JA Bonner","year":"2010","unstructured":"Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [published correction appears in Lancet Oncol 2010 Jan; 11(1):14]. Lancet Oncol 11:21\u201328","journal-title":"Lancet Oncol"},{"key":"1817_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12916-014-0203-5","volume":"12","author":"WX Qi","year":"2014","unstructured":"Qi WX, Fu S, Zhang Q et al (2014) Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. BMC Med 12:203","journal-title":"BMC Med"},{"key":"1817_CR25","doi-asserted-by":"publisher","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","volume":"23","author":"B Burtness","year":"2005","unstructured":"Burtness B, Goldwasser MA, Flood W et al (2005) Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646\u20138654","journal-title":"J Clin Oncol"},{"key":"1817_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","volume":"14","author":"JB Vermorken","year":"2013","unstructured":"Vermorken JB, St\u00f6hlmacher-Williams J, Davidenko I et al (2013) Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 14:697\u2013710","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01817-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01817-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01817-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T02:17:45Z","timestamp":1659061065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01817-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1817"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01817-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Yokota serves in an advisory role for Merck Biopharma, MSD, and Rakuten Medical, and has received lecture fees from Merck Biopharma, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, AstraZeneca, Chugai, MSD, and Eisai. All authors received research funding from Merck Biopharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}